

(43) International Publication Date
24 September 2015 (24.09.2015)

(51) International Patent Classification:

C07D 401/06 (2006.01) A61K 31/497 (2006.01)
C07D 241/28 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/GB2015/050765

(22) International Filing Date:

17 March 2015 (17.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/954,674 18 March 2014 (18.03.2014) US

(71) Applicant (for all designated States except IR, MG): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).(72) Inventors: **BERGLUND, Susanne, Elisabeth**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **CONNOLLY, Stephen**; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **HEMMERLING, Martin**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **HOSSAIN, Nafizal**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **KRISTOFFERSSON, Anna**; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **LUNDKVIST, Johan, Rune, Michael**; C/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **NIKITID-**

IS, Grigorios; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **RIPA, Lena, Elisabeth**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **SHAMOVSKY, Igor**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: The present invention provides a compound of a formula (I); or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).